Hot spots in prion protein for pathogenic conversion

Prion proteins are key molecules in transmissible spongiform encephalopathies (TSEs), but the precise mechanism of the conversion from the cellular form (PrPC) to the scrapie form (PrPSc) is still unknown. Here we discovered a chemical chaperone to stabilize the PrPC conformation and identified the hot spots to stop the pathogenic conversion. We conducted in silico screening to find compounds that fitted into a “pocket” created by residues undergoing the conformational rearrangements between the native and the sparsely populated high-energy states (PrP*) and that directly bind to those residues. Forty-four selected compounds were tested in a TSE-infected cell culture model, among which one, 2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide, termed GN8, efficiently reduced PrPSc. Subsequently, administration of GN8 was found to prolong the survival of TSE-infected mice. Heteronuclear NMR and computer simulation showed that the specific binding sites are the A-S2 loop (N159) and the region from helix B (V189, T192, and K194) to B-C loop (E196), indicating that the intercalation of these distant regions (hot spots) hampers the pathogenic conversion process. Dynamics-based drug discovery strategy, demonstrated here focusing on the hot spots of PrPC, will open the way to the development of novel anti-prion drugs.

[1]  O. Bocharova,et al.  In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). , 2005, Journal of molecular biology.

[2]  R. Riek,et al.  NMR structure of the mouse prion protein domain PrP(121–231) , 1996, Nature.

[3]  B. Caughey,et al.  Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.

[4]  W. Caughey,et al.  Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.

[5]  P E Wright,et al.  Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Caughey,et al.  Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds? , 2006, Accounts of chemical research.

[7]  S. Prusiner,et al.  Locally disordered conformer of the hamster prion protein: a crucial intermediate to PrPSc? , 2002, Biochemistry.

[8]  S. Prusiner.  Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[9]  D. Dormont,et al.  A novel generation of heparan sulfate mimetics for the treatment of prion diseases. , 2003, The Journal of general virology.

[10]  Seiichiro Ogawa,et al.  Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Prusiner,et al.  Molecular biology and transgenetics of prion diseases. , 1991, Critical reviews in biochemistry and molecular biology.

[12]  R J Fletterick,et al.  Structural clues to prion replication. , 1994, Science.

[13]  R. Gabizon,et al.  The Anti-prion Activity of Congo Red , 1998, The Journal of Biological Chemistry.

[14]  I. Gilbert,et al.  Synthesis of analogues of Congo red and evaluation of their anti-prion activity. , 2004, Journal of medicinal chemistry.

[15]  J. Ávila,et al.  Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. , 1998, The Biochemical journal.

[16]  B. Caughey,et al.  New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products , 2003, Journal of Virology.

[17]  B. Caughey,et al.  Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[19]  D. Harris,et al.  Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein , 2000, Journal of Virology.

[20]  Francesco Fiorito,et al.  Prion protein NMR structures of elk and of mouse/elk hybrids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[22]  T. Iwaki,et al.  Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies , 2006, Journal of neurochemistry.

[23]  J. Laplanche,et al.  Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt‐Jakob disease phenotype , 2000, Human mutation.

[24]  C. Korth,et al.  A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations. , 2006, Journal of medicinal chemistry.

[25]  F. Cohen,et al.  Mimicking dominant negative inhibition of prion replication through structure-based drug design. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Cohen,et al.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Chabry,et al.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs , 2003, Journal of Cell Science.

[28]  A. Mangé,et al.  Effect of Congo Red on Wild‐Type and Mutated Prion Proteins in Cultured Cells , 2000, Journal of neurochemistry.

[29]  T. James,et al.  Slow conformational dynamics in the hamster prion protein. , 2004, Biochemistry.

[30]  S. Prusiner,et al.  A Change in the Conformation of Prions Accompanies the Emergence of a New Prion Strain , 2002, Neuron.

[31]  E. Zuiderweg,et al.  Mapping protein-protein interactions in solution by NMR spectroscopy. , 2002, Biochemistry.

[32]  A. Favier,et al.  Prion infection impairs the cellular response to oxidative stress. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Chang,et al.  Oxidative folding of murine prion mPrP(23-231). , 2001, European journal of biochemistry.

[34]  F. Cohen,et al.  Elimination of prions by branched polyamines and implications for therapeutics. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Fred E. Cohen,et al.  Evidence for assembly of prions with left-handed β-helices into trimers , 2004 .

[36]  S. Prusiner,et al.  A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[37]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Steven Pratt,et al.  Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance. , 2006, Journal of pharmaceutical and biomedical analysis.

[39]  Andrew D. Steele,et al.  Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F E Cohen,et al.  Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Dobson,et al.  Low-populated folding intermediates of Fyn SH3 characterized by relaxation dispersion NMR , 2004, Nature.

[42]  F. Cohen,et al.  Structure−Activity Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based Compounds: Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics. , 2007 .

[43]  R Abagyan,et al.  Rational discovery of novel nuclear hormone receptor antagonists , 2000, Proc. Natl. Acad. Sci. USA.

[44]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[45]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[46]  Claudio Soto,et al.  Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. , 2006, Trends in biochemical sciences.

[47]  A. Aguzzi,et al.  No propagation of prions in mice devoid of PrP , 1994, Cell.

[48]  K. Wüthrich,et al.  Prion protein NMR structures of cats, dogs, pigs, and sheep. , 2005, Proceedings of the National Academy of Sciences of the United States of America.